NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 01/29/2024 at 12:30, 9 months 23 days ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV

NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
PRESS RELEASE

published on 01/04/2024 at 12:30, 10 months 17 days ago

NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections.

NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE

published on 11/28/2023 at 12:40, 11 months 23 days ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE

published on 11/15/2023 at 12:45, 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE

published on 11/14/2023 at 12:45, 1 year ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE

published on 10/16/2023 at 12:45, 1 year 1 month ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE

published on 10/12/2023 at 12:45, 1 year 1 month ago

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE

published on 08/21/2023 at 12:45, 1 year 3 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE

published on 07/11/2023 at 12:45, 1 year 4 months ago

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE

published on 07/06/2023 at 12:45, 1 year 4 months ago

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

Published on 11/21/2024 at 16:01, 11 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 12 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 12 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 12 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:30, 42 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 12 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 30 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 48 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 49 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 14 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 14 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 14 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 4 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 52 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News